Autor: John D. Lambris

Progress and Trends in Complement Therapeutics.- Inhibition of the serine proteases of the complement system.- The role of MASP-1/3 in complement activation.- Membrane-bound complement regulatory proteins as biomarkers and potential therapeutic targets for SLE.- DAF as a therapeutic target for steroid hormones: implications for host pathogen interactions.- Targeting g C1q R domains for therapy against infection and inflammation.- The Alternative C5a Receptor Function.- The effects of selective complement- and CD14-inhibition on the E. coli-induced tissue factor m RNA up-regulation, monocyte tissue factor expression and tissue factor functional activity in human whole blood.- CR2-Mediated Targeting of Complement Inhibitors: Bench-to-Bedside Using a Novel Strategy for Site-Specific Complement Modulation.- Paroxysmal nocturnal hemoglobinuria and the complement system: recent insights and novel anti-complement strategies.- Defective Complement Action and Control Defines Disease Pathology for Retinal and Renal Disorders and Provides a Basis for new Therapeutic Approaches.- C3 Glomerulonephritis/CFHR5 Nephropathy is an endemic disease in Cyprus: Clinical and molecular findings in 21 families.- Complement-targeted therapeutics in periodontitis.- Complement system activation in cardiac and skeletal muscle pathology: Friend or foe?.- Innate immunity as orchestrator of bone marrow homing for hematopoietic stem/progenitor cells.- Complement-mediated microvascular injury leads to chronic rejection.- Targeting complement at the time of transplantation.- Evaluation of the blood compatibility of materials, cells and tissues: Basic concepts, test models and practical guidelines.- Highly Multiplexed Proteomic Platform for Biomarker Discovery, Diagnostics and Therapeutics.- Complement in Action: A Review of Patent Trends From 1976 through 2011.